Company intelligence / Profile preview
LongBio Pharma
Shanghai, Shanghai, Chinalongbio.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Other
01
Overview
LP-003 (anti-IgE antibody) is in Phase III and preparing for pre-BLA in 2025H2. It has shown superior improvement compared to Omalizumab in CSU Phase II trials. LP-005 (bifunctional complement inhibitor) is in Phase II for PNH. LP-001 is in Phase I for anemia.
- Therapeutic areas
- PulmonologyNephrologyOphthalmologyImmunologyDermatologyHematologyNeurology
- Modalities
- AntibodiesFusion proteinsBiologics
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on LongBio Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LongBio Pharma.